We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Tool Detects Breast Cancer Relapses Five Years in Advance

By LabMedica International staff writers
Posted on 23 Jun 2025

Relapse detection in patients with solid tumors—particularly hormone receptor-positive (HR+) breast cancer—remains a major clinical challenge, as many patients initially respond well to treatment but later relapse without early warning signs. More...

Traditional diagnostic methods often fail to detect these relapses in time due to limited sensitivity. Now, a new blood-based tool offers a minimally invasive solution that can identify signs of relapse months—sometimes years—before symptoms become clinically detectable.

The innovation, by Altum Sequencing (Madrid, Spain), a start-up supported by the C3N-IA Science Park at Universidad Carlos III de Madrid (UC3M, Getafe, Spain), aims to transform post-treatment follow-up in solid tumors by leveraging advanced sequencing technologies. At the tool's core is the use of next-generation sequencing (NGS) to analyze circulating tumor DNA (ctDNA)—small fragments of tumor-derived DNA found in the blood. The process starts with an initial biopsy to identify patient-specific mutations. Subsequent blood tests monitor for these specific mutations, allowing the detection of even one tumor cell among a million healthy ones. By concentrating only on mutations relevant to each patient, the approach enhances precision while reducing costs and the likelihood of false positives. The study, published in Breast Cancer Research, showed that the technology could detect clinical relapses in HR+ breast cancer patients up to 68 months before conventional diagnostic methods would typically identify them.

Given that up to 40% of patients with this subtype of breast cancer eventually relapse, this early detection window could dramatically alter patient outcomes by initiating timely intervention. The solution is not only personalized and highly sensitive but also broadly applicable across various types of solid tumors, thanks to its adaptable methodology. Its minimally invasive nature makes it ideal for regular monitoring, avoiding unnecessary treatments, and enhancing patient comfort. Altum is currently pursuing regulatory approvals in both Europe and the United States, aiming to bring this technology to hospitals worldwide. Looking ahead, the company is also planning to integrate generative artificial intelligence into its platform. Having already implemented machine learning algorithms to enhance diagnostics, Altum now seeks to further boost diagnostic accuracy, treatment customization, and delivery of actionable patient information through the use of AI.

"We started with hematological cancers such as multiple myeloma and acute myeloid leukemia, but we are already seeing good results in lung cancers as well, so our goal is to transform cancer monitoring," said Marina Planas, CEO of Altum Sequencing. “Today, we can detect one cell in a million. In the future, it will be one in ten million.”

Related Links:
Altum Sequencing
UC3M


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The cell-based tests bring artificial intelligence to transplant outcome care (Photo courtesy of iStock)

AI-Enhanced Cell-Based Blood Tests to Improve Predictive Accuracy for Complex Transplant Outcomes

Managing immunosuppressive drugs in transplant patients is a delicate challenge. Insufficient medication can lead to rejection, which may be cell- or antibody-mediated, while excess immunosuppression raises... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Pathology

view channel
Image: A saliva test can help predict future metabolic health concerns including diabetes and obesity (Photo courtesy of 123RF)

Saliva Test to Enable Early Detection of Diabetes and Obesity

Type 2 diabetes affects about 400 million people globally and is typically diagnosed through elevated blood glucose levels. However, conditions like insulin resistance and hyperinsulinemia may begin developing... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.